NCT03977649View on ClinicalTrials.gov

A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

July 5, 2021

Study Completion Date

July 5, 2021

Conditions
Migraine Disorders
Interventions
DRUG

erenumab

erenumab 140 mg sc every 4 weeks

DRUG

placebo

placebo sc every 4 weeks

Trial Locations (5)

20132

Novartis Investigative Site, Milan

20133

Novartis Investigative Site, Milan

27100

Novartis Investigative Site, Pavia

80138

Novartis Investigative Site, Napoli

Unknown

Novartis Investigative Site, L’Aquila

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY